Evaluation of Rivaroxaban Exposure via Anti-Xa Levels During VTE Prophylaxis in Hospitalized Patients.

Clin Appl Thromb Hemost · 2025 · PMC11808744 · PMID 39925048

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The secondary outcomes assessing the relationship between rivaroxaban drug concentrations and time since administration, r 2 = 0.16 ( P = .049), as well as time since administration of rivaroxaban and anti-Xa activity, r 2 = 0.15 ( P = .066), were weakly correlated and showed a trend.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.